{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:21:59Z","timestamp":1794921719891,"version":"4.9.1"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1038\/s41581-026-01109-6","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:15:15Z","timestamp":1785924915000},"page":"869-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The therapeutic approach to cardiovascular\u2013kidney\u2013metabolic syndrome"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-7891","authenticated-orcid":false,"given":"Janani","family":"Rangaswami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Kevin Bryan","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiadi E.","family":"Ndumele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"1109_CR1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular\u2013kidney\u2013metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"1109_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. A synopsis of the evidence for the science and clinical management of cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148, 1636\u20131664 (2023).","journal-title":"Circulation"},{"key":"1109_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","volume":"86","author":"M Packer","year":"2025","unstructured":"Packer, M. The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment. J. Am. Coll. Cardiol. 86, 1269\u20131373 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1109_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.kint.2025.09.019","volume":"109","author":"SL Furth","year":"2025","unstructured":"Furth, S. L. et al. The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 109, 442\u2013464 (2025).","journal-title":"Kidney Int."},{"key":"1109_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007264","volume":"13","author":"J Rangaswami","year":"2020","unstructured":"Rangaswami, J., Tuttle, K. & Vaduganathan, M. Cardio\u2013renal\u2013metabolic care models: toward achieving effective interdisciplinary care. Circ. Cardiovasc. Qual. Outcomes 13, e007264 (2020).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"1109_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan, S. S. et al. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation 149, 430\u2013449 (2024).","journal-title":"Circulation"},{"key":"1109_CR7","unstructured":"PREVENT risk calculator. American Heart Association https:\/\/professional.heart.org\/en\/guidelines-and-statements\/prevent-calculator (2023)."},{"key":"1109_CR8","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"1109_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"ET Group","year":"2009","unstructured":"Group, E. T. et al. Strict blood-pressure control and progression of renal failure in children. N. Engl. J. Med. 361, 1639\u20131650 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamapediatrics.2024.5552","volume":"179","author":"RR Putri","year":"2025","unstructured":"Putri, R. R. et al. Effect of pediatric obesity treatment on long-term health. JAMA Pediatr. 179, 302\u2013309 (2025).","journal-title":"JAMA Pediatr."},{"key":"1109_CR11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2337\/dca25-0027","volume":"48","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Transition of BMI status from childhood to adulthood and cardiovascular-kidney-metabolic syndrome in midlife: a 36-year cohort study. Diabetes Care 48, 2045\u20132053 (2025).","journal-title":"Diabetes Care"},{"key":"1109_CR12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","volume":"151","author":"SE Hampl","year":"2023","unstructured":"Hampl, S. E. et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 151, e2022060640 (2023).","journal-title":"Pediatrics"},{"key":"1109_CR13","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 81, 492\u2013542 (2024)."},{"key":"1109_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/01.CIR.0000048892.83521.58","volume":"107","author":"EG Lakatta","year":"2003","unstructured":"Lakatta, E. G. & Levy, D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a \u201cset up\u201d for vascular disease. Circulation 107, 139\u2013146 (2003).","journal-title":"Circulation"},{"key":"1109_CR15","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1161\/01.cir.0000437740.48606.d1","volume":"129","author":"RH Eckel","year":"2014","unstructured":"Eckel, R. H. et al. 2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. Circulation 129, S76\u2013S99 (2014).","journal-title":"Circulation"},{"key":"1109_CR16","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","volume":"146","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones, D. M. et al. Life\u2019s essential 8: updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation 146, e18\u2013e43 (2022).","journal-title":"Circulation"},{"key":"1109_CR17","first-page":"CD015328","volume":"5","author":"F Spiga","year":"2024","unstructured":"Spiga, F. et al. Interventions to prevent obesity in children aged 5 to 11 years old. Cochrane Database Syst. Rev. 5, CD015328 (2024).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1109_CR18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","volume":"344","author":"J Tuomilehto","year":"2001","unstructured":"Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343\u20131350 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1152\/physrev.00014.2016","volume":"97","author":"DJ Green","year":"2017","unstructured":"Green, D. J., Hopman, M. T., Padilla, J., Laughlin, M. H. & Thijssen, D. H. Vascular adaptation to exercise in humans: role of hemodynamic stimuli. Physiol. Rev. 97, 495\u2013528 (2017).","journal-title":"Physiol. Rev."},{"key":"1109_CR20","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jcmg.2020.10.019","volume":"14","author":"J Henzel","year":"2021","unstructured":"Henzel, J. et al. High-risk coronary plaque regression after intensive lifestyle intervention in nonobstructive coronary disease: a randomized study. JACC Cardiovasc. Imaging 14, 1192\u20131202 (2021).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"1109_CR21","first-page":"1388","volume":"379","author":"RAH Stewart","year":"2018","unstructured":"Stewart, R. A. H. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N. Engl. J. Med. 379, 1388 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101788","volume":"4","author":"I Shahid","year":"2025","unstructured":"Shahid, I. et al. Lifestyle interventions in cardiovascular\u2013kidney\u2013metabolic syndrome JACC: Advances expert panel. JACC Adv. 4, 101788 (2025).","journal-title":"JACC Adv."},{"key":"1109_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/oby.23154","volume":"29","author":"C Gallagher","year":"2021","unstructured":"Gallagher, C., Corl, A. & Dietz, W. H. Weight can\u2019t wait: a guide to discussing obesity and organizing treatment in the primary care setting. Obesity 29, 821\u2013824 (2021).","journal-title":"Obesity"},{"key":"1109_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jama.2014.10432","volume":"312","author":"RF Kushner","year":"2014","unstructured":"Kushner, R. F. & Ryan, D. H. Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews. JAMA 312, 943\u2013952 (2014).","journal-title":"JAMA"},{"key":"1109_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082973","volume":"14","author":"O Hamer","year":"2024","unstructured":"Hamer, O. et al. Psychological interventions for weight reduction and sustained weight reduction in adults with overweight and obesity: a scoping review. BMJ Open 14, e082973 (2024).","journal-title":"BMJ Open"},{"key":"1109_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1037\/hea0000576","volume":"37","author":"A Jacob","year":"2018","unstructured":"Jacob, A. et al. Impact of cognitive-behavioral interventions on weight loss and psychological outcomes: a meta-analysis. Health Psychol. 37, 417\u2013432 (2018).","journal-title":"Health Psychol."},{"key":"1109_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","volume":"2","author":"I Caruso","year":"2024","unstructured":"Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S. & Giorgino, F. Incretin-based therapies for the treatment of obesity-related diseases. npj Metab. Health Dis. 2, 31 (2024).","journal-title":"npj Metab. Health Dis."},{"key":"1109_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.2011.1914","volume":"307","author":"L Sjostrom","year":"2012","unstructured":"Sjostrom, L. et al. Bariatric surgery and long-term cardiovascular events. JAMA 307, 56\u201365 (2012).","journal-title":"JAMA"},{"key":"1109_CR29","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. J. Am. Coll. Cardiol. 79, 1757\u20131780 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1109_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"1109_CR31","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","volume":"142","author":"J Rangaswami","year":"2020","unstructured":"Rangaswami, J. et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation 142, e265\u2013e286 (2020).","journal-title":"Circulation"},{"key":"1109_CR32","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari, S. et al. Renin\u2013angiotensin system inhibition in advanced chronic kidney disease. N. Engl. J. Med. 387, 2021\u20132032 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR33","first-page":"1718","volume":"40","author":"N Vendeville","year":"2024","unstructured":"Vendeville, N., Lepage, M. A., Festa, M. C. & Mavrakanas, T. A. Clinical outcomes of renin\u2013angiotensin\u2013aldosterone blockade in patients with advanced chronic kidney disease: a systematic review and meta-analysis. Can. J. Cardiol. 40, 1718\u20131728 (2024).","journal-title":"Can. J. Cardiol."},{"key":"1109_CR34","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/M23-3236","volume":"177","author":"E Ku","year":"2024","unstructured":"Ku, E. et al. Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: a systematic review and retrospective individual participant-level meta-analysis of clinical trials. Ann. Intern. Med. 177, 953\u2013963 (2024).","journal-title":"Ann. Intern. Med."},{"key":"1109_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","volume":"95","author":"BF Palmer","year":"2020","unstructured":"Palmer, B. F. Potassium binders for hyperkalemia in chronic kidney disease\u2013diet, renin\u2013angiotensin\u2013aldosterone system inhibitor therapy, and hemodialysis. Mayo Clin. Proc. 95, 339\u2013354 (2020).","journal-title":"Mayo Clin. Proc."},{"key":"1109_CR36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J. et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman, K. et al. Renal effects and associated outcomes during angiotensin\u2013neprilysin inhibition in heart failure. JACC Heart Fail. 6, 489\u2013498 (2018).","journal-title":"JACC Heart Fail."},{"key":"1109_CR38","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","volume":"142","author":"FR Mc Causland","year":"2020","unstructured":"Mc Causland, F. R. et al. Angiotensin\u2013neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 142, 1236\u20131245 (2020).","journal-title":"Circulation"},{"key":"1109_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf224","volume":"18","author":"A Covic","year":"2025","unstructured":"Covic, A. et al. Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi\/ARB: a systematic review and meta-analysis. Clin. Kidney J. 18, sfaf224 (2025).","journal-title":"Clin. Kidney J."},{"key":"1109_CR40","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/ehf2.13002","volume":"7","author":"F Spannella","year":"2020","unstructured":"Spannella, F., Giulietti, F., Filipponi, A. & Sarzani, R. Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. ESC Heart Fail. 7, 3487\u20133496 (2020).","journal-title":"ESC Heart Fail."},{"key":"1109_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","volume":"2","author":"AS Desai","year":"2017","unstructured":"Desai, A. S. et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2, 79\u201385 (2017).","journal-title":"JAMA Cardiol."},{"key":"1109_CR42","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes, R. et al. Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138, 1505\u20131514 (2018).","journal-title":"Circulation"},{"key":"1109_CR43","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel, S. M. et al. Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. Circulation 149, 1789\u20131801 (2024).","journal-title":"Circulation"},{"key":"1109_CR44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M. et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400, 757\u2013767 (2022).","journal-title":"Lancet"},{"key":"1109_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100933","volume":"36","author":"R Cardoso","year":"2021","unstructured":"Cardoso, R. et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine 36, 100933 (2021).","journal-title":"EClinicalMedicine"},{"key":"1109_CR46","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","volume":"335","author":"BL Neuen","year":"2026","unstructured":"Neuen, B. L. et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA 335, 233\u2013244 (2026).","journal-title":"JAMA"},{"key":"1109_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jama.2025.20835","volume":"335","author":"N Staplin","year":"2026","unstructured":"Staplin, N. et al. Effects of sodium glucose cotransporter 2 inhibitors by diabetes status and level of albuminuria: a meta-analysis. JAMA 335, 220\u2013232 (2026).","journal-title":"JAMA"},{"key":"1109_CR48","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh, T. A. et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 44, 3627\u20133639 (2023).","journal-title":"Eur. Heart J."},{"key":"1109_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129\u2013139 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117\u2013128 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR51","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","volume":"13","author":"R Aggarwal","year":"2025","unstructured":"Aggarwal, R. et al. Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial. Lancet Diabetes Endocrinol. 13, 321\u2013332 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1109_CR52","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","volume":"44","author":"M Packer","year":"2023","unstructured":"Packer, M. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors. Eur. Heart J. 44, 5027\u20135035 (2023).","journal-title":"Eur. Heart J."},{"key":"1109_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054442","volume":"8","author":"U Panchapakesan","year":"2013","unstructured":"Panchapakesan, U. et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells \u2014 renoprotection in diabetic nephropathy? PLoS ONE 8, e54442 (2013).","journal-title":"PLoS ONE"},{"key":"1109_CR54","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder, J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97, 1020\u20131031 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1109_CR55","doi-asserted-by":"publisher","first-page":"117090","DOI":"10.1016\/j.lfs.2019.117090","volume":"240","author":"H Yaribeygi","year":"2020","unstructured":"Yaribeygi, H., Sathyapalan, T., Maleki, M., Jamialahmadi, T. & Sahebkar, A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review. Life Sci. 240, 117090 (2020).","journal-title":"Life Sci."},{"key":"1109_CR56","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini, E., Mark, M. & Mayoux, E. CV Protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care 39, 1108\u20131114 (2016).","journal-title":"Diabetes Care"},{"key":"1109_CR57","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen, B. L. et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145, 1460\u20131470 (2022).","journal-title":"Circulation"},{"key":"1109_CR58","doi-asserted-by":"publisher","first-page":"102664","DOI":"10.1016\/j.cpcardiol.2024.102664","volume":"49","author":"KB Bhanushali","year":"2024","unstructured":"Bhanushali, K. B., Asnani, H. K., Nair, A., Ganatra, S. & Dani, S. S. Pharmacovigilance study for SGLT 2 inhibitors \u2014 safety review of real-world data and randomized clinical trials. Curr. Probl. Cardiol. 49, 102664 (2024).","journal-title":"Curr. Probl. Cardiol."},{"key":"1109_CR59","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.2337\/dc24-0946","volume":"47","author":"FM Gao","year":"2024","unstructured":"Gao, F. M. et al. A systematic review and meta-analysis on the safety and efficacy of sodium-glucose cotransporter 2 inhibitor use in hospitalized patients. Diabetes Care 47, 2275\u20132290 (2024).","journal-title":"Diabetes Care"},{"key":"1109_CR60","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.3390\/jcm13216509","volume":"13","author":"JJ Gorgojo-Martinez","year":"2024","unstructured":"Gorgojo-Martinez, J. J., Gorriz, J. L., Cebrian-Cuenca, A., Castro Conde, A. & Velasco Arribas, M. Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: a multidisciplinary expert consensus. J. Clin. Med. 13, 6509 (2024).","journal-title":"J. Clin. Med."},{"key":"1109_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86172-y","volume":"15","author":"S Hunsuwan","year":"2025","unstructured":"Hunsuwan, S. et al. Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease. Sci. Rep. 15, 1667 (2025).","journal-title":"Sci. Rep."},{"key":"1109_CR62","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309\u20131321 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR63","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11\u201321 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR65","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131, 34\u201342 (2015).","journal-title":"Circulation"},{"key":"1109_CR66","volume":"10","author":"EY Chung","year":"2020","unstructured":"Chung, E. Y. et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev. 10, CD007004 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1109_CR67","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","volume":"8","author":"N Tofte","year":"2020","unstructured":"Tofte, N. et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 8, 301\u2013312 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1109_CR68","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","volume":"30","author":"FDR Hobbs","year":"2024","unstructured":"Hobbs, F. D. R. et al. Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nat. Med. 30, 3634\u20133645 (2024).","journal-title":"Nat. Med."},{"key":"1109_CR69","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","volume":"406","author":"P Rossignol","year":"2025","unstructured":"Rossignol, P. et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet 406, 705\u2013718 (2025).","journal-title":"Lancet"},{"key":"1109_CR70","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","volume":"406","author":"M Walsh","year":"2025","unstructured":"Walsh, M. et al. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. Lancet 406, 695\u2013704 (2025).","journal-title":"Lancet"},{"key":"1109_CR71","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","volume":"39","author":"M Kobayashi","year":"2024","unstructured":"Kobayashi, M., Girerd, N. & Zannad, F. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases. Nephrol. Dial. Transpl. 39, 1063\u20131072 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1109_CR72","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252\u20132263 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR73","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR74","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ndt\/gfae132","volume":"40","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink, H. J. L. et al. Design and baseline characteristics of the finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease (FIND-CKD) randomized trial. Nephrol. Dial. Transpl. 40, 308\u2013319 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1109_CR75","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06307652 (2024)."},{"key":"1109_CR76","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon, S. D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 391, 1475\u20131485 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR77","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan, M. et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat. Med. 30, 3758\u20133764 (2024).","journal-title":"Nat. Med."},{"key":"1109_CR78","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack, J. M. et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N. Engl. J. Med. 393, 1363\u20131374 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR79","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena, M. et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial. JAMA 334, 409\u2013418 (2025).","journal-title":"JAMA"},{"key":"1109_CR80","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06268873 (2024)."},{"key":"1109_CR81","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06677060 (2025)."},{"key":"1109_CR82","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","volume":"40","author":"PK Judge","year":"2025","unstructured":"Judge, P. K. et al. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrol. Dial. Transpl. 40, 1175\u20131186 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1109_CR83","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06424288 (2024)."},{"key":"1109_CR84","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06935370 (2025)."},{"key":"1109_CR85","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3390\/biomedicines13081924","volume":"13","author":"A Gajjar","year":"2025","unstructured":"Gajjar, A. et al. SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular-kidney-metabolic syndrome. Biomedicines 13, 1924 (2025).","journal-title":"Biomedicines"},{"key":"1109_CR86","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776\u2013785 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1109_CR87","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR88","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun, H. M. et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. 30, 2058\u20132066 (2024).","journal-title":"Nat. Med."},{"key":"1109_CR89","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2025","unstructured":"Apperloo, E. M. et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat. Med. 31, 278\u2013285 (2025).","journal-title":"Nat. Med."},{"key":"1109_CR90","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire, D. K. et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N. Engl. J. Med. 392, 2001\u20132012 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR91","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR92","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N. Engl. J. Med. 390, 1394\u20131407 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR93","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR94","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls, S. J. et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N. Engl. J. Med. 393, 2409\u20132420 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR95","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2337\/db18-0317","volume":"68","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. GLP-1 receptor in pancreatic alpha-cells regulates glucagon secretion in a glucose-dependent bidirectional manner. Diabetes 68, 34\u201344 (2019).","journal-title":"Diabetes"},{"key":"1109_CR96","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal. Transduct. Target. Ther. 9, 234 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1109_CR97","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2337\/db12-1025","volume":"62","author":"D Wang","year":"2013","unstructured":"Wang, D. et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP\/PKA\/Rho-dependent mechanism. Diabetes 62, 1697\u20131708 (2013).","journal-title":"Diabetes"},{"key":"1109_CR98","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmstadter","year":"2020","unstructured":"Helmstadter, J. et al. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 40, 145\u2013158 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1109_CR99","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1055\/s-0034-1371892","volume":"46","author":"S Nakashima","year":"2014","unstructured":"Nakashima, S., Matsui, T., Takeuchi, M. & Yamagishi, S. I. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products\u2013receptor axis. Horm. Metab. Res. 46, 717\u2013721 (2014).","journal-title":"Horm. Metab. Res."},{"key":"1109_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05753-z","volume":"22","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome\/PFKFB3-driven glycolysis interaction and histone lactylation. J. Transl. Med. 22, 954 (2024).","journal-title":"J. Transl. Med."},{"key":"1109_CR101","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type\u00a02 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519\u20131529 (2018).","journal-title":"Lancet"},{"key":"1109_CR102","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3803\/EnM.2024.1940","volume":"39","author":"JW Son","year":"2024","unstructured":"Son, J. W. & Lim, S. Glucagon-like peptide-1 based therapies: a new horizon in obesity management. Endocrinol. Metab. 39, 206\u2013221 (2024).","journal-title":"Endocrinol. Metab."},{"key":"1109_CR103","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.3390\/diagnostics14242829","volume":"14","author":"SP Osei","year":"2024","unstructured":"Osei, S. P. et al. Gastrointestinal safety assessment of GLP-1 receptor agonists in the us: a real-world adverse events analysis from the FAERS database. Diagnostics 14, 2829 (2024).","journal-title":"Diagnostics"},{"key":"1109_CR104","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker, D. J. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 47, 1873\u20131888 (2024).","journal-title":"Diabetes Care"},{"key":"1109_CR105","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2337\/dc18-2028","volume":"42","author":"MA Bethel","year":"2019","unstructured":"Bethel, M. A. et al. Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the exenatide study of cardiovascular event lowering (EXSCEL). Diabetes Care 42, 1075\u20131080 (2019).","journal-title":"Diabetes Care"},{"key":"1109_CR106","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/10600280231205490","volume":"58","author":"K Wilhite","year":"2024","unstructured":"Wilhite, K., Reid, J. M. & Lane, M. Risk of pancreatitis with incretin therapies versus thiazolidinediones in the veterans health administration. Ann. Pharmacother. 58, 685\u2013689 (2024).","journal-title":"Ann. Pharmacother."},{"key":"1109_CR107","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"DW Jones","year":"2025","unstructured":"Jones, D. W. et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. J. Am. Coll. Cardiol. 86, 1567\u20131678(2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1109_CR108","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","volume":"46","author":"SC Naaman","year":"2023","unstructured":"Naaman, S. C. & Bakris, G. L. Diabetic nephropathy: update on pillars of therapy slowing progression. Diabetes Care 46, 1574\u20131586 (2023).","journal-title":"Diabetes Care"},{"key":"1109_CR109","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","volume":"40","author":"RZ Alicic","year":"2025","unstructured":"Alicic, R. Z., Neumiller, J. J. & Tuttle, K. R. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrol. Dial. Transpl. 40, i3\u2013i17 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1109_CR110","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof, P. et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52, 642\u2013652 (2021).","journal-title":"Am. J. Nephrol."},{"key":"1109_CR111","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z. et al. Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. Results of a randomized controlled trial with Col4a3\u2212\/\u2212 mice. J. Am. Soc. Nephrol. 34, 1513\u20131520 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1109_CR112","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","volume":"33","author":"M Provenzano","year":"2022","unstructured":"Provenzano, M. et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J. Am. Soc. Nephrol. 33, 1569\u20131580 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1109_CR113","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal, R. et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N. Engl. J. Med. 393, 533\u2013543 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR114","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ndt\/gfaf160","volume":"41","author":"M Vaduganathan","year":"2025","unstructured":"Vaduganathan, M. et al. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial. Nephrol. Dial. Transpl. 41, 161\u2013170 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1109_CR115","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen, B. L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 7, 845\u2013854 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1109_CR116","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.121.057934","volume":"145","author":"CSP Lam","year":"2022","unstructured":"Lam, C. S. P. et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation 145, 565\u2013574 (2022).","journal-title":"Circulation"},{"key":"1109_CR117","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2337\/dc25-1080","volume":"49","author":"JFE Mann","year":"2026","unstructured":"Mann, J. F. E. et al. Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: results from the SOUL randomized trial. Diabetes Care 49, 257\u2013265 (2026).","journal-title":"Diabetes Care"},{"key":"1109_CR118","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. 30, 2849\u20132856 (2024).","journal-title":"Nat. Med."},{"key":"1109_CR119","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen, B. L. et al. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation 150, 1781\u20131790 (2024).","journal-title":"Circulation"},{"key":"1109_CR120","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing, P. et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the fidelity analysis. Diabetes Care 45, 2991\u20132998 (2022).","journal-title":"Diabetes Care"},{"key":"1109_CR121","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296\u20131305 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1109_CR122","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae228","volume":"17","author":"S Maruyama","year":"2024","unstructured":"Maruyama, S. et al. Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan. Clin. Kidney J. 17, sfae228 (2024).","journal-title":"Clin. Kidney J."},{"key":"1109_CR123","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","unstructured":"Writing Group for the CKD Prognosis Consortium et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA 330, 1266\u20131277 (2023).","journal-title":"JAMA"},{"key":"1109_CR124","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302\u2013308 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1109_CR125","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2215\/CJN.02980322","volume":"17","author":"KR Tuttle","year":"2022","unstructured":"Tuttle, K. R. et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 17, 1092\u20131103 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1109_CR126","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2215\/CJN.0000000857","volume":"21","author":"KR Tuttle","year":"2025","unstructured":"Tuttle, K. R. et al. A real-world cohort study of the risks of kidney failure and death in diabetes. Clin. J. Am. Soc. Nephrol. 21, 83\u201394 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1109_CR127","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.069382","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen, B. L. et al. Timing of cardio-kidney protection with SGLT2 inhibitors: insights from 4 large-scale placebo-controlled outcome trials. Circulation 150, 343\u2013345 (2024).","journal-title":"Circulation"},{"key":"1109_CR128","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan, S. S. et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular\u2013kidney\u2013metabolic health: a scientific statement from the American Heart Association. Circulation 148, 1982\u20132004 (2023).","journal-title":"Circulation"},{"key":"1109_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101009","volume":"22","author":"M Ambrosio","year":"2025","unstructured":"Ambrosio, M. et al. Performance of prevent and pooled cohort equations for predicting 10-year ASCVD risk in the UK Biobank. Am. J. Prev. Cardiol. 22, 101009 (2025).","journal-title":"Am. J. Prev. Cardiol."},{"key":"1109_CR130","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/s41591-025-03789-2","volume":"31","author":"RO Mathew","year":"2025","unstructured":"Mathew, R. O. et al. Performance of the American Heart Association\u2019s PREVENT risk score for cardiovascular risk prediction in a multiethnic population. Nat. Med. 31, 2655\u20132662 (2025).","journal-title":"Nat. Med."},{"key":"1109_CR131","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/jamacardio.2025.1865","volume":"10","author":"X Yan","year":"2025","unstructured":"Yan, X. et al. Performance of the American Heart Association\u2019s prevent equations among disaggregated racial and ethnic subgroups. JAMA Cardiol. 10, 876\u2013885 (2025).","journal-title":"JAMA Cardiol."},{"key":"1109_CR132","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jacc.2025.08.001","volume":"86","author":"SS Khan","year":"2025","unstructured":"Khan, S. S. et al. Use of risk assessment to guide decision-making for blood pressure management in the primary prevention of cardiovascular disease: a scientific statement from the American Heart Association and American College of Cardiology. J. Am. Coll. Cardiol. 86, 1539\u20131559 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1109_CR133","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jamacardio.2025.2725","volume":"10","author":"SS Khan","year":"2025","unstructured":"Khan, S. S. et al. Statin eligibility according to atherosclerotic cardiovascular disease risk in the US. JAMA Cardiol. 10, 1071\u20131073 (2025).","journal-title":"JAMA Cardiol."},{"key":"1109_CR134","unstructured":"Evidence review for the best combination of measures to identify increased risk of progression in adults, children and young people. In Chronic Kidney Disease: Evidence Review F: NICE Evidence Reviews Collection (National Institute for Health and Care Excellence, 2021)."},{"key":"1109_CR135","doi-asserted-by":"publisher","first-page":"596","DOI":"10.7326\/0003-4819-158-8-201304160-00004","volume":"158","author":"N Tangri","year":"2013","unstructured":"Tangri, N. et al. Risk prediction models for patients with chronic kidney disease: a systematic review. Ann. Intern. Med. 158, 596\u2013603 (2013).","journal-title":"Ann. Intern. Med."},{"key":"1109_CR136","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788\u20131801 (2022)."},{"key":"1109_CR137","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1681\/ASN.2020050723","volume":"31","author":"M Oshima","year":"2020","unstructured":"Oshima, M. et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J. Am. Soc. Nephrol. 31, 2925\u20132936 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1109_CR138","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 7, 128\u2013139 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1109_CR139","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh, J. et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 7, 115\u2013127 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1109_CR140","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/dc20-2839","volume":"44","author":"R Krist\u00f3fi","year":"2021","unstructured":"Krist\u00f3fi, R. et al. Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study. Diabetes Care 44, 1211\u20131218 (2021).","journal-title":"Diabetes Care"},{"key":"1109_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110908","volume":"204","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial. Diabetes Res. Clin. Pract. 204, 110908 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1109_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-026-01078-w","author":"LA Mavromatis","year":"2026","unstructured":"Mavromatis, L. A. & Grams, M. E. Epidemiology of cardiovascular\u2013kidney\u2013metabolic syndrome. Nat. Rev. Nephrol. https:\/\/doi.org\/10.1038\/s41581-026-01078-w (2026).","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01109-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01109-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01109-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:03:52Z","timestamp":1794920632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01109-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":142,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01109-6","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"30 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R. is an employee of the Veterans Health administration. The content of this manuscript does not reflect those of the Veterans Health administration. J.R. served as co-chair for the scientific advisory group for the AHA\u2019s CKM Health Presidential Advisory. She reports serving as a consultant for Boehringer Ingelheim\/Lily, Bayer and Procyrion Inc. K.B.L. is under NIH T32HL007604 training grant. C.E.N. served as the chair of the scientific advisory group for the AHA\u2019s CKM Health Presidential Advisory, and has no other relevant disclosures.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}